March 3, 2025
Geert Kersten discusses how CEL-SCI is taking a critical step forward in the fight against head and neck cancer with the initiation of the Multikine Confirmatory Phase 3 Trial—a pivotal study that could bring this innovative immunotherapy one step closer to FDA approval and commercialization.

• Here is the link

November 22, 2024
Geert Kersten discusses the implications of the FDA’s Oncologic Drugs Advisory Committee (ODAC) decision on checkpoint inhibitors for patients with low or negative PD-L1 expression and the significance to CEL-SCI.

• Here is the link

October 21, 2024
An interview with Geert Kersten discussing the unique approach CEL-SCI has to fight cancer.

• Here is the link

October 23, 2023
A presentation delivered by Geert Kersten Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.

• Here is the link

September 2022
An oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer. This presentation includes data presented at the European Society for Medical Oncology (ESMO) Annual Congress in September 2022.

• Here is the link

July 13, 2021
Interview with Geert Kersten on Rense Radio

• Here is the link

May 2019

Geert Kersten presentation at The Hard Asset Conference

May 2019

Interview with Geert Kersten, Chief Executive Officer, aired on Phoenix TV.

March 2019

Interview with Geert Kersten, Chief Executive Officer on Midas Letter

October 2018

Interview with Geert Kersten, Chief Executive Officer.

January 2016

Interview with Dr. Eyal Talor, Chief Scientific Officer